---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-046268"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2026-10-08T12:40:39+00:00"
generated_at: "2026-10-12T15:36:09.877534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Beyond Air preannounces Q3 revenue of $2.3M, up 30% sequentially and 27% YoY; reaffirms CY2026/CY2027 guidance

## Summary
- Preliminary unaudited revenue of ~$2.3 million for the quarter ended September 30, 2026, the highest quarterly revenue reported to date.
- Revenue rose about 30% versus the quarter ended June 30, 2026 and 27% versus the same quarter last year on LungFit PH adoption.
- Guidance reaffirmed: $8 million for CY2026 (excludes second-generation LungFit PH) and $16-$18 million for CY2027 (includes second-gen, pending FDA approval).
- Second-generation LungFit PH remains under FDA review via an ongoing PMA supplement; adding transport capability would make Beyond Air a single-source nitric oxide provider.
- CEO Robert Goodman credits the enhanced commercial execution strategy; full Q3 results will be reported in November 2026.

## SEC filing metadata
- accession: 0001493152-26-046268
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2026-10-08T12:40:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000149315226046268/0001493152-26-046268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000149315226046268/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-046268
- JSON: https://secwatch.observer/filing/0001493152-26-046268.json
- Plain text: https://secwatch.observer/filing/0001493152-26-046268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.